Interim Report for the period April – June 2022

FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...

Interim Report for the period January – March 2022

Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...

BioArctic publishes the Annual Report for 2021

Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...

Proud partner of: